EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Achieving dynamic efficiency in pharmaceutical innovation: Identifying the optimal share of value and payments required

Beth Woods iD, James Lomas iD, Mark Sculpher, Helen Weatherly, Karl Claxton iD

Health Economics · 2024-04 · 33 (4) · 804-819

DOI: 10.1002/hec.4795 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Health Economics, online erschienen am 16.01.2024. Verfasst von Beth Woods und 4 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Health Economics, University of York, York, UK. Hauptthemen laut MEDLINE: State Medicine, Drug Industry. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health and Care Research, Policy Research Unit in Economic Methods of Evaluation in Health and Social Care Interventions.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

It has been argued that cost‐effectiveness analysis of branded pharmaceuticals only considers static efficiency, neglects dynamic effects and undermines incentives for socially valuable innovation. We present a framework for designing pharmaceutical pricing policy to achieve dynamic efficiency. We develop a coherent framework that identifies the long‐term static and dynamic benefits and costs of offering manufacturers different levels of reward. The share of value that would maximise long‐term population health depends on how the quantity and quality of innovation responds to payment. Using evidence of the response of innovation to payment, the optimal share of value of new pharmaceuticals to offer to manufacturers is roughly 20% (range: 6%–51%). Reanalysis of a sample of NICE technology appraisals suggests that, in most cases, the share of value offered to manufacturers and the price premium paid by the English NHS were too high. In the UK, application of optimal shares would offer considerable benefits under both a public health objective and a broader view of social welfare. We illustrate how an optimal share of value can be delivered through a range of payment mechanisms including indirect price regulation via the use of different approval norms by an HTA body.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

State MedicineDrug IndustryHumansCosts and Cost AnalysisSocial WelfarePharmaceutical Preparations

Stichwörter der Autor:innen

analysis of health care marketsdynamic efficiencygovernment policypharmaceutical pricingpublic healthregulationstatic efficiency

Substanzen

Pharmaceutical Preparations

Autor:innen und Institutionen

  • Centre for Health Economics, University of York, York, UK.
  • Department of Economics and Related Studies, University of York, York, UK.

ORCID-Profile: Beth Woods, James Lomas, Karl Claxton

Förderung

  • National Institute for Health and Care Research
  • Policy Research Unit in Economic Methods of Evaluation in Health and Social Care Interventions

Zitieren

APA

Woods, B., Lomas, J., Sculpher, M., Weatherly, H., & Claxton, K. (2024). Achieving dynamic efficiency in pharmaceutical innovation: Identifying the optimal share of value and payments required. Health Economics, 33(4), 804-819. https://doi.org/10.1002/hec.4795

Vancouver

Woods B, Lomas J, Sculpher M, Weatherly H, Claxton K. Achieving dynamic efficiency in pharmaceutical innovation: Identifying the optimal share of value and payments required. Health Economics. 2024;33(4):804-819. doi:10.1002/hec.4795

BibTeX
@article{Woods2024,
  author = {Woods, Beth and Lomas, James and Sculpher, Mark and Weatherly, Helen and Claxton, Karl},
  title = {Achieving dynamic efficiency in pharmaceutical innovation: Identifying the optimal share of value and payments required},
  journal = {Health Economics},
  year = {2024},
  volume = {33},
  number = {4},
  pages = {804--819},
  doi = {10.1002/hec.4795}
}
Kostenlos starten →